Trilegal, SAM, Khaitan, Ropes act on India Resurgence Fund ₹992 crore investment in Panacea BiotecMay 15 2019
India Resurgence Fund, promoted by Piramal Enterprises and Bain Capital Credit, has invested ₹992 crore in drug firm Panacea Biotec.
This investment is structured by way of non-convertible debentures (NCDs) of up to ₹864 crore and subscription amount of ₹32 crore towards share warrants to be allotted on a preferential basis, reported Mint.
Trilegal and Ropes & Gray acted for the investors.
Nishant Parikh, Anirudh Agarwala, Arjun Ghose, Kunaal Shah
|Sneha Vardhan, Tejas Adiga||
Senior Associates: Anshul Gosavi, Samira Lalani, Aakriti Shakdher, Sneha Agnihotri, Deep Choudhuri, Rahil Pereira
Associates: Kartik Adhlakha, Snigdha Guha Roy, Srirang Sapre, Deepan Shah, Payal Desai, Ritwik Dash, Akshaya Venkataraman, Gazzal Bishnoi, Vaibhavi Shaunak, Maitreya Shaunak, Nayan Jain, Vruiti Patel, Vaishali Movva
Shardul Amarchand Mangaldas & Co advised Panacea Biotec
|Sam & Co||Partner||Associates|
|Corporate||Abhinav Bhalaik||Principal Associate: Daryush Marfatia, Senior Associates: Neekesh Shetty, Gaurav Dugar,
Associates: Chirag Shah, Purva Phadke, Tanay Khanna, Harshvardhan Sunder and Gauri Pathak.
|Due Diligence||Abhinav Bhalaik
Asmita Kerkar, Neekesh ShettyAssociates: Tanvee
Vasudevan, Devika Menon, Avni Merchant, Purva Phadke, Shradha Nigam
|Banking & Finance||Sapan Gupta
|Senior Associate: G. Meenakshi
Associate: Swati Lal
Khaitan & Co acted for one of the promoters of the company.
With a premium account you get:
- One year of unrestrcited access to previous interviews, columns and articles
- One year access to all archival material
- Access to all Bar & Bench reports